<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590965</url>
  </required_header>
  <id_info>
    <org_study_id>2014-013-00CH1</org_study_id>
    <nct_id>NCT02590965</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fruquintinib Plus Best Supportive Care in Patients With Advanced Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial&#xD;
      to evaluate the efficacy and safety of Fruquintinib plus best supportive care in patients&#xD;
      with advanced non-squamous non-small cell lung cancer who failed to second-line standard&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 90 subjects will be randomized to Fruquintinib plus best supportive care or&#xD;
      placebo plus best supportive care at a 2:1 ratio.&#xD;
&#xD;
      Randomization will be stratified by EGFR (epidermal growth factor receptor) gene status:&#xD;
      mutant vs. wild type vs. unknown.&#xD;
&#xD;
      All subjects will receive Fruquintinib/placebo for consecutive 3 weeks, followed by one-week&#xD;
      rest. A treatment cycle consists of 4 weeks. Tumor assessment will be performed every 4 weeks&#xD;
      in the first 3 cycles, and every 8 weeks since the 4th cycle, until disease progression.&#xD;
      Further treatment and survival follow-up after progression will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2014</start_date>
  <completion_date type="Actual">February 10, 2017</completion_date>
  <primary_completion_date type="Actual">August 7, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progressive free survival (PFS)</measure>
    <time_frame>measured every 4 weeks at first 2 cycles and every 8 weeks since the third cycle from randomization to disease progression, assessed up to one year</time_frame>
    <description>To compare the Progressive Free Survival (PFS) of Fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients advanced non-squamous NSCLC patients who failed to standard second-line chemotherapy according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>measured every 4 weeks at first 2 cycles and every 8 weeks since the third cycle from randomization to disease progression, assessed up to one year</time_frame>
    <description>To evaluate objective response rate (ORR) in the two groups according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>measured every 4 weeks at first 2 cycles and every 8 weeks since the third cycle from randomization to disease progression, assessed up to one year</time_frame>
    <description>To evaluate disease control rate (DCR) in the two groups according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>every 2 months from randomization to death, assessed up to one year</time_frame>
    <description>To evaluate overall survival (OS) in the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability by incidence, severity and outcome of adverse events</measure>
    <time_frame>From randomization to 30 days after last dose</time_frame>
    <description>To evaluate the safety and tolerability in the two groups by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is a capsule in the form of 1mg and 5 mg, orally, once daily, 3 weeks on/1week off with best supportive care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive oral Fruquintinib at fasting state 5mg+best supportive care, once daily for the first 3 consecutive weeks and dose holiday for 1 week according to their dose regimens until the occurrence of disease progression, unacceptable toxicity, or withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib</intervention_name>
    <description>After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>HMPL-013</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>HMPL-013-placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fully understand the study and sign the informed consent form voluntarily;&#xD;
&#xD;
          2. Histologically and/or cytologically diagnosed with local advanced and/or metastatic&#xD;
             stage IIIB/IV non-squamous NSCLC;&#xD;
&#xD;
          3. Previously failed to two chemotherapy regimens(treatment failure is defined as disease&#xD;
             progression or intolerable toxicity), patients with positive EGFR mutation permitted&#xD;
             to treated by EGFR-TKI previously; patients with EGFR wild type or unknown whether or&#xD;
             not treated by EGFR-TKI previously;&#xD;
&#xD;
          4. Aged 18-75 years (inclusive);&#xD;
&#xD;
          5. Body weight ≥40 kg;&#xD;
&#xD;
          6. Evident measurable lesion(s) (according to RECIST1.1);&#xD;
&#xD;
          7. ECOG Performance Status 0-1;&#xD;
&#xD;
          8. Expected survival &gt;12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment in another clinical trials in the past 3 weeks; or treatment with systemic&#xD;
             anti-tumor chemotherapy, radiotherapy or biotherapy within 3 weeks prior to&#xD;
             administration of the study drug;&#xD;
&#xD;
          2. Previous therapy with VEGF/VEGFR inhibitors;&#xD;
&#xD;
          3. Unrecovered from toxicity caused by previous anti-cancer treatment (CTCAE &gt;grade 1),&#xD;
             or not completely recovered from previous surgery;&#xD;
&#xD;
          4. Previous active brain metastasis (without radiotherapy previously, or symptoms stable&#xD;
             &lt; 4 weeks, or with clinical symptoms, or with medication to control symptoms);&#xD;
&#xD;
          5. Other malignancies except basal cell carcinoma or cervical carcinoma in situ in the&#xD;
             past 5 years;&#xD;
&#xD;
          6. Uncontrolled clinical active infection, e.g. acute pneumonia and active hepatitis B;&#xD;
&#xD;
          7. Dysphagia or known drug malabsorption;&#xD;
&#xD;
          8. Present active duodenal ulcer, ulcerative colitis, intestinal obstruction and other&#xD;
             gastrointestinal diseases or other conditions that may lead to gastrointestinal&#xD;
             bleeding or perforation according to the investigators' judgment; or with a history of&#xD;
             intestinal perforation or intestinal fistula;&#xD;
&#xD;
          9. Have evidence or a history of thrombosis or bleeding tendency, regardless of&#xD;
             seriousness;&#xD;
&#xD;
         10. Stroke and/or transient ischemic attack within 12 months prior to enrollment;&#xD;
&#xD;
         11. Appropriate organ function. Patients with any of the following conditions will be&#xD;
             excluded:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt;1.5×109/L, platelet &lt;100×109/L or hemoglobin &lt;9&#xD;
                  g/dL within 1 week prior to enrollment;&#xD;
&#xD;
               -  Serum total bilirubin &gt;1.5 upper limit of normal (ULN), alanine transaminase and&#xD;
                  aspartate transferase &gt;1.5×ULN; ALT and AST &gt; 3×ULN in patients with liver&#xD;
                  metastasis;&#xD;
&#xD;
               -  Electrolyte abnormality of clinical significance;&#xD;
&#xD;
               -  Blood creatinine &gt;ULN and creatinine clearance &lt;60 ml/min;&#xD;
&#xD;
               -  Urine protein 2+ or above, or 24 h urine protein quantification ≥1.0 g/24 h;&#xD;
&#xD;
               -  Activated partial thromboplastin time (APTT) or/and INR and prothrombin time (PT)&#xD;
                  &gt;1.5×ULN (according to reference range in each clinical study center);&#xD;
&#xD;
         12. Uncontrolled hypertension, systolic blood pressure ≥140 mmHg and/or diastolic blood&#xD;
             pressure ≥90 mmHg with medication; or heart failure NYHA classification ≥ grade 2;&#xD;
&#xD;
         13. Heart function evaluation: left ventricular ejection fraction &lt;50% (echocardiography);&#xD;
&#xD;
         14. Acute myocardial infarction, severe/unstable angina or coronary bypass surgery within&#xD;
             6 months prior to enrollment; history of arterial thrombosis or deep venous&#xD;
             thrombosis;&#xD;
&#xD;
         15. Skin wound, surgical site, wound site, severe mucosal ulcer or fracture without&#xD;
             complete healing;&#xD;
&#xD;
         16. Female subjects who are pregnant or lactating or of child bearing potential with&#xD;
             positive pregnancy test result before the first dose;&#xD;
&#xD;
         17. Patients with child bearing potential who or whose sexual partners are not willing to&#xD;
             take contraceptive measures;&#xD;
&#xD;
         18. Any clinical or laboratory abnormalities unfit to participate in this clinical trial&#xD;
             according to the investigator's judgment;&#xD;
&#xD;
         19. Serious psychological or psychiatric disorders which may affect subject compliance in&#xD;
             this clinical study;&#xD;
&#xD;
         20. Allergy to Fruquintinib and/or excipient contained in trial drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>307 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xi Nan Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantong Tumor Hospital</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linyi Tumor Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hosptial of College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

